The findings of the current study are supported by other studies that have shown CHK1 inhibitors to be effective as single agents in defined tumour genetic backgrounds [50–52]; such as those with activating KRAS or MYC mutations, loss-of-function ATM or TP53 mutations, or with repair gene defects. This evidence concerns the gene TP53 and neoplasm.